Advisory Services Network
KYTX icon

Advisory Services Network’s Kyverna Therapeutics KYTX Stock Holding History

Advisory Services Network’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-86
Closed -$742 – 4700
2026
Q1 		$742 Buy
+86
New +$717 ﹤0.01% 4362
2025
Q4 		– Sell
-86
Closed -$516 – 4325
2025
Q3 		$516 Buy
+86
New +$344 ﹤0.01% 4051

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
Gilead Sciences
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bain Capital Life Sciences Investors
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.6B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Insight Holdings Group
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Advisory Services Network's KYTX Position: Q2 2026 in Review

Advisory Services Network sold out of Kyverna Therapeutics (KYTX) in Q2 2026, closing a stake of 86 shares — an estimated $742 sold.

Advisory Services Network first reported a position in KYTX in Q3 2025 and held it in 2 quarters. The position peaked at $742 in Q1 2026. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Advisory Services Network reported no remaining Kyverna Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Advisory Services Network sold 86 Kyverna Therapeutics shares in Q2 2026, an estimated $742.
  • Advisory Services Network first reported a position in Kyverna Therapeutics in Q3 2025 and held it in 2 quarters.
  • Advisory Services Network's Kyverna Therapeutics position peaked at $742 in Q1 2026.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Advisory Services Network's 13F filing for Q2 2026, filed 12 Aug 2026.